Effects of Berberine on Blood Glucose, Glycated Hemoglobin A₁, Serum Insulin, C–Peptide, Insulin Resistance and β–Cell Physiology

Haji Khan Khoharo¹, Din Muhammad Shaikh¹, Ghulam Shah Nizamani², Tariq Zaffar Shaikh³, Ikramuddin Ujjan⁴ and Arslan Ahmed Uqaili¹

¹Department of Physiology, Faculty of Medicine & Allied Medical Sciences, Isra University, Hyderabad, Sindh, Pakistan.
²Department of Pathology/Hematology, Faculty of Medicine & Allied Medical Sciences, Isra University, Hyderabad, Sindh, Pakistan.
³Department of Medicine, Liaquat University of Medical and Health Sciences, Hospital, Jamshoro/Hyderabad, Sindh, Pakistan.
⁴Department of Pathology, Liaquat University of Medical and Health Sciences, Hospital Jamshoro/Hyderabad, Sindh, Pakistan.

Authors’ contributions

This work was carried out in collaboration among all authors. Authors HKK, DMS and GSN designed the study, performed the statistical analysis, wrote the protocol and wrote the first draft of the manuscript. Authors HKK, TZS and IU managed the biochemical analysis and analyses of the study. Author HKK and AAU managed the literature searches. All authors read and approved the final manuscript.

ABSTRACT

Objective: Determine effects of berberine (BBR) on blood glucose, glycated hemoglobin A₁, serum insulin, C – peptide, insulin resistance and β– cell physiology.

Study Design: Experimental study

Place and Duration: Department of Physiology Isra University and Animal house of Sindh Agriculture University, Tando Jam from August 2019 to February 2020.
Diabetes mellitus (DM) is a glucose metabolic disorder caused primarily by dysfunction of β-cells of endocrine pancreas. DM is an endocrinopathy of chronic hyperglycemia caused by relative and/or absolute insulin deficiency. Currently 415 million of World population is suffering from DM, and is estimated to 624 million by the 2040 year [1]. DM claims 5 million lives yearly, mainly by the coronary artery and chronic renal diseases [1,2]. Diabetic causailities may be reduced by tight glycemic control [3]. Lifestyle modificatin is initial protocol to reach a glycemic control [4]. It is reproted that OHAs are efficacious in 41% diaebtics in achieving optimal glycemic control [4]. Metformin causes gut irritation and diarrhoea [5]. Berberine (BBR) is a herbal agent derived from Chinese rhizomacoptidis of berberis family. BBR is a traditional Chinese medicine extracted from berberis and other plants. BBR is considered the “secret prescription” of China [6]. Previous studies [7,8] compared the BBR and meformin in clinical trials and found BBR efficacy similar to metformin. Later study found increased insulin receptor expression by BBR [8]. A previous study [8] found insignificant glucose lowering potential of BBR, although cholesterol and systemic blood pressure were reduced significantly. Numerous studies [9-11] have reproted hypoglycemiac efficacy of BBR, but its efficacy has not been confirmed in terms of β– cell physiology and Insulin resistance. Prevalence and incidence of DM is increasing in the country, and growing interest has been observed in the alternative herbal remedy for the diabetic populations with least side effects. The present experimental study analysed effects of berberine on glucose homeostasis, β– cell secretory function (HOMA-β %) and Insulin resistance (HOMA-IR %) in alloxan induced diabetic rats.

2. METHODOLOGY

The present experimental study was conducted at the animal house of Sindh Agriculture University, Tando Jam. It was conduced from August 2018 to July 2019 (one year duration). A sample of 100 adult Wistar male rats was selected according to criteria of study. Adult albino Wistar male rats looking healthy, feeding well, and body weight 150- 200 grams qualified for inclusion. Female rats, unhealthy, lazy and sick male rats and rats of different body weight were excluded. Rats were purchased from the Animal Husbandry & Veterinary Sciences Department, Sindh Agriculture University Tando Jam. Animal housing fulfilled the critera of NIH, Updated National Research Council, USA Committee “Guidelines for the Care and Use of Lab Animals” [12]. Wooden saw dust was used for bedding of animals. Rats were kept in stainless steel cages that were equipped with plastic drinkers. Feed was kept in the steel feed containers. Hygienic standards of animal house were observed strictly. Tap water was available ad libitum. Dark- light cycles of 12/12 hours was ensured. Animals were divided into five groups by random technique.

2.1 Animal Grouping

Rat groups; Group A – negative controls (N/S 0.9%), Group B – positive control (diabetic experimental group) (Alloxan 120 mg/kg) intra - peritoneal (i.p) (No BBR drug therapy) [13],
Group C – Diabetic rat received BBR (50 mg/kg), Group D – Diabetic rat received BBR (100 mg/kg) and Group E – Diabetic rat received BBR (200 mg/kg) daily for 6 weeks [14].

2.2 Experimental Procedure

Experimental procedure included phase I and II. In phase I, the animals were selected by purposive – sampling technique to fulfill the inclusion and exclusion criteria.

2.3 Induction of DM

The animals were injected Alloxan 120 mg/kg intra - peritoneal (i.p) to induce diabetes. Alloxan (Sigma - Aldrich, St. Louis, MO, USA) was purchased from broker (World scientific, Pakistan). It was kept at low temperature (4°C). Alloxan was dissolved in the 0.9% N/S and injected in rats fasting for an overnight. Dose of Alloxan used - 120 mg/kg bwt intraperitoneal [13]. DM was confirmed glucose level ≥ 250 mg/dl at 72 hours. After successful DM induction, the rats were randomly divided into positive control and experimental groups.

2.4 Animal Handling

Institutional ethics of experimental animal handling was adhered strictly. Diet was prepared by commercial feed (~40%), wheat flour (~40%) and dry milk (~20%). BBR was administrated mixed in diet at 50 mg, 100 mg and 200 mg/Kg body weight [14].

2.5 Experimental Details

At the end of experiment, the rats were anesthetized by Ethylene- ether and blood samples were collected from retro-orbital venous plexus by capillary tube.

2.6 Biochemical Analysis

Samples were collected in EDTA and Plain tubes. Sera were taken by blood centrifuged at 3000 rpm (15 minutes), and stored -20°C. HbA1c was detected by TINIA method. C-peptide and serum insulin levels were detected by Elisa assay kit according to the method mentioned. Insulin resistance (HOMA-IR %) was calculated as Glucose (mmol/L) x Insulin (mU/L)/22.5 [15]. Insulin Resistance (IR) was defined as No IR <1.0, early IR <1.9, moderate IR >1.9 - <2.5 and severe IR >2.5 [15]. HOMA-β% was calculated as Insulin (mU/L) x20/Glucose (mmol/L)-3.5 [15].

2.7 Statistical Analysis

Statistical analysis was performed on SPSS version 21.0 (IBM, incorporation, USA). Analysis of variance (ANOVA) and post – hoc Tuckey Cramer test were used for the continuous variables with normal Gaussian distribution. Significance of analysis was taken at 95% CI (P≤ 0.05).

3. RESULTS

Findings of fasting blood glucose (FBG), random blood glucose (RBG), HbA1c, Insulin, C-peptide, Insulin resistance (HOMA-IR) and β – cell function (HOMA – β) revealed significant improvement after 6 weeks BBR therapy (Table-1). FBG was reduced by -23%, -30% and -35% in BBR treated experimental groups C, D and E (P=0.0001). RBG showed reduction by -23%, -30% and -35% in BBR treated experimental groups C, D and E (P=0.0001). HbA1c was decreased by -25%, -18% and -6% in BBR treated experimental groups C, D and E (P=0.0001). C–peptide shows increase of 213%, 180% and 61% in BBR treated experimental groups C, D and E (P=0.0001). Insulin resistance (HOMA-IR %) and β – cell physiology (HOMA-β %) shows significant improvement as shown in Fig. 1.

4. DISCUSSION

The present research observed the physiological efficacy of Berberine (BBR) for its glucose homeostasis, β-cell physiology and Insulin resistance in alloxan induced diabetic male Wistar rat model. FBG was reduced by -23%, -30% and -35% (P=0.0001) and RBG reduced by -23%, -30% and -35% (P=0.0001). Glucose lowering potential of BBR is in agreement with previous studies [16,17]. Hypoglycemic effects are exerted through liver gluconeogenesis inhibitin [18], enhanced glucokinase activity [19] and increased insulin secretion through Islets of Langerhans regeneration [20]. Reduction in insulin resistance (HOMA-IR) is in agreement with previous study [21]. Previous studies [22, 23] found insignificant hypoglycemic activity of BBR that is in contrast to present and previous studies [17,18]. Conflicting result of above studies [22,23] are most probably because of different doses and duration of BBR therapy and research bias. In present study, the hypoglycemic effect was prominent after 6 weeks BBR therapy. Another reason of conflicting results is hypoglycemic activity of BBR is dose dependent [23]. In present study, the significant
reduction was noted in HbA1c of BBR treated experimental groups C, D and E. Findings are in accordance to previous studies [16-18]. A recent study [19] reviewed BBR therapy and life style modification were significantly effective (P=0.001) in improving the HbA1c compared to placebo alone. Our finding of improved glycemric control is consistent to previous studies [24,16,17]. A recent 3T3-L1 adipocyte model [25] witnessed the glucose and HbA1c lowering potential of BBR therapy. Another study [26] noted the anti hyperglycemic activity of BBR in diabetic db/db mice was mediated through enhanced liver glucokinase (GK) expression. In present study, the HbA1c was reduced by -6% group C, -18% in group D and -25% in group E in comparison to positive control group B (P=0.0001). Finding is consistent with previous studies [26,27]. Huang et al [28] noted 11.1% HbA1c reduction from baseline after 12 weeks of Rhizoma coptis (BBR). In present study, the serum insulin and Insulin resistance (HOMA-IR %) were reduced and β – cell physiology (HOMA-β %) was improved. Findings are in agreement with previous studies [16-18]. In present study, the insulin resistance (HOMA-IR) shows reduction of 24% in group C, -60% group D and -70% group E (P=0.0001) after 6 weeks BBR therapy. The β- cell activity (HOMA-β) improved by +2%, +18% and +82% in BBR treated groups C, D and E respectively (P=0.0001). Findings are in agreement with previous studies [27-29]. Previous studies [16,18,26] noticed glucose and fasting insulin reduction and improved β- cell physiology and insulin sensitivity in (RIR) rat model. Reduction in insulin resistance is in agreement with a previous study [29] that noted improved insulin resistance, fasting and random blood glucose and serum insulin levels at 3 months of BBR therapy in type 2 diabetics. The findings of present study are also supported by recent studies [16,19,29]. In present study, the fasting plasma insulin (FPI) and insulin resistance (HOMA-IR) were reduced by -14.1% and -27.3% respectively this is in agreement with previous study [29]. Amelioration of HOMA-IR of present study is in agreement with previous studies [27-30]. The β – cell physiology (HOMA-β) of present study shows improvement of +2%, +18% and +82% in BBR.

| Table 1. Biochemical findings in controls and experimental rats |
|---------------------------------------------------------------|
| **Group** | **FBG** | 79.2±11.3 | 290.1±23.4 | 223.1±33.3 | 202.1±41.2 | 188.9±55.3 | 0.0001 |
|           | **RBG** | 123.1±8.7 | 399.0±34.2 | 323.1±9.9  | 320.8±18.8 | 207.6±29.4 | 0.0002 |
|           | **HbA1c** | 5.1±0.6  | 8.66±0.72 | 8.14±0.69  | 7.08±0.78  | 6.4±0.50  | 0.0001 |
|           | **Insulin** | 11.27±0.7 | 3.6±0.89 | 4.3±1.1  | 4.8±1.1  | 6.4±0.50  | 0.0003 |
|           | **C-peptide** | 1.74±0.6 | 0.4±0.27 | 1.01±0.15 | 1.13±0.1 | 1.27±0.20 | 0.0005 |
|           | **HOMA-IR** | 0.64±0.31 | 4.55±1.07 | 3.4±0.38 | 1.82±0.7 | 1.35±0.20 | 0.0001 |
|           | **HOMA-β** | 85.80±14.7 | 27.90±16.8 | 27.23±7.6 | 30.24±9.3 | 50.8±4.4 | 0.0001 |

![Insulin Resistance and β-cell physiology](image)

**Fig. 1. Relative % increase/decrease in Insulin resistance (HOMA-IR) and β – cell physiology (HOMA-β)**
treated groups C, D and E respectively, the finding is consistent with previous studies [30,31]. In the present study, serum C-peptide shows increase of 213%, 180% and 61% in low to high dose BBR treated experimental rats respectively. Finding is in agreement with previous studies [32,33]. The findings of present study are in favor of berberine exerting glucose lowering effects through improved insulin resistance and β–cell physiology.

5. CONCLUSION

In conclusion, the present study shows berberine (BBR) ameliorates blood glucose, glycated hemoglobin A1, serum insulin, insulin resistance and β-cell physiology. Further experimental and clinical studies are recommended. Berberine shows promising results for a more natural type of diabetes therapy through β–cell stimulation.

CONSENT

It is not applicable.

ETHICAL APPROVAL

Ethical and Research Committee of Isra university (Letter # IU/RR-10/D(M&27/2016/1573).

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Almani SA, Memon IA, Shaikh TZ, Koharo HK, Uijan I. Berberine protects against metformin-associated lactic acidosis in induced diabetes mellitus. Iran J Basic Med Sci. 2017;20:511-515. DOI: 10.22038/IJBM.S.2017.8675
2. Almani SA, Qureshi F, Shaikh TZ, Uqaili AA, Koharo HK. Free radical scavenging activity of berberine in aceticaminophen induced liver injury. Int’l J Surgery Med. 2017;3(1):27-36.
3. Xie W, Zhao Y, Zhang Y. Traditional Chinese medicines in treatment of patients with type 2 diabetes mellitus. Evid Based Complement Alternat Med. 2011;726723.
4. Agarwal AA, Jadhav PR, Deshmukh YA. Prescribing pattern and efficacy of anti-diabetic drugs in maintaining optimal glycemic levels in diabetic patients. J Basic Clin Pharm. 2014;5:79–83.
5. Tokajuk A, Krzyzanowska G, Tokajuk A, Grycel S, Sadowska A, Car H. Antidiabetic drugs and risk of cancer. Pharmacol Rep. 2015;67:1240–1250.
6. Zhong Y, Jin J, Liu P, Song Y, Zhang H, Sheng L, et al. Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice. Oxidative Med Cell Longevity 2020; Article ID 6210526:1-8.
7. Changrong G, Yingbiao Z, Yiping Y, Riqiu C. Study on the evaluation of curative effect of berberine in the treatment of type 2 diabetes and its safety. China Modern Doctor. 2017;33:82–3384 (In Chinese).
8. Zhang H, Wei J, Xue R, Wu J, Zhao W. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. 2010;59:285–292.
9. Hu Y, Ehli EA, Kittelsrud J, Ronan PJ, Munger K, et al. Lipid-lowering effect of berberine in human subjects and rats. Phytomedicine. 2012;19:861–867.
10. Lan J, Zhao Y, Dong F, Yan Z, Zheng W. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2014;161:69–81.
11. Zhu J, Wang X, Lv W, Ji X. Gliclazide combined with berberine in the treatment of type 2 diabetes mellitus. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine. 2015;25:915–917 (In Chinese)
12. National Institute of Health. Guide for the Care and Use of Laboratory Animals, 8th Edn. Washington, DC: The National Academies Press. 2010:13-7.
13. Maithili V, Dhanabal SP, Mahendran S, Vadivelan R. Antidiabetic activity of ethanolic extract of tubers of Dioscorea alata in alloxan induced diabetic rats Indian J Pharmacol. 2011;43(4):455–459.
14. Li XY, Zhao ZX, Huang M, Feng R, He CY, Ma C, et al. Effect of Berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters. J Transl Med. 2015;13:278.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9.
16. Ramezani J, Azabayjani MA, Peer M. Simultaneous Effects of Aerobic Training and Berberine Chloride on Plasma Glucose, IL-6 and TNF-α in Type 1 Diabetic Male Wistar Rats. Nutr Food Sci Res. 2016;6(1):9-16.

17. Jia D, Li ZW, Zhou X, Gao Y, Fegn Y, Ma M, et al. A novel berberine-metformin hybrid compound exerts therapeutic effects on obese type 2 diabetic rats. Clin Exp Pharmacol Physiol 2019;46(6):533-544.

18. Jiang S, Dong H, Li JB, Xu LJ, Zou X, Wang KF, et al. Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin induced diabetic rats. World J. Gastroenterol 2015; 21: 7777– 85.

19. Zhang Q, Xiao O, Feng K, Wang T, Li W, Yuan T, et al. Berberine moderates glucose and lipid metabolism through multi pathway mechanism. Evid Based Complement Alternat Med. 2011;9:24851.

20. Leng SH, Lu FE, Xu LJ. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacologica Sinica. 2004;25:496–502.

21. Wang Y, Campbell T, Perry B, Beaurepaire C, Qin L. Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet and streptozotocin-induced diabetic rats. Metabolism. 2011;60:298–305.

22. Hu Y, Ehli EA, Kittelsrud J, Ronan PJ, Munger K, Downey T, et al. Lipid-lowering effect of berberine in human subjects and rats. Phytomedicine. 2012;19:661–67.

23. Febbraio MA, Pedersen BK. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J. 2002;16(11):1335–47.

24. Cao Y. Clinical research on multiple factor intervention of improving the insulin resistance. Shandong University of Traditional Chinese Medicine (In Chinese). 2007;12-9.

25. Lou H, Gao X, Jin J, Wang F, Peng P, Han Y, et al. Effects of different concentrations of berberine on 3T3-L1 adipocyte glycometabolism and inflammatory cytokine expression. Int’l J Clin Exp Med. 2019;12(7):8366-8373.

26. Li M, Dang Y, Li Q, Zhou W, Zuo J, Yao Z, et al. Berberine alleviates hyperglycemia by targeting hepatic glucokinase in diabetic db/db mice. Scientific Reports. 2019;9:8003.

27. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55(8):2256-2264.

28. Huang YH, Chen ST, Liu FH, Hsieh SH, Lin CH, Liou MJ, et al. The efficacy and safety of concentrated herbal extract granules, YH1, as an add-on medication in poorly controlled type 2 diabetes: A randomized, double-blind, placebo-controlled pilot trial. PLoS ONE. 2019;14(8):e0221199.

29. Cicero AFG, Fogacci F, Bove M, Colletti A, Veronesi M, Giovanni M, Borghi C. Effects of a combined nutraceutical on glucose and lipid metabolism in women with post-menopausal incident metabolic syndrome: a double-blind, placebo-controlled, randomized clinical trial. J Food Nut Metabol. 2019;2(2):6-6.

30. Yin J, Xing H, Ye J. Efficacy of Berberine in Patients with Type 2 Diabetes. Metabolism: clinical and experimental. 2008;57(5):712–7.

31. Chueh WH, Lin JY. Protective effect of berberine on serum glucose levels in non-obese diabetic mice. Int Immunopharmacol [Internet]. 2012;12(3):534–8.

32. Yin YW, Sun QQ, Zhang BB, Hu AM, Wang Q, Liu HL, et al. The lack of association between interleukin-6 gene−174 G/C polymorphism and the risk of type 1 diabetes mellitus: A meta-analysis of 18,152 subjects. Gene. 2013;515(2):461–5.

33. Yang N, Sun RB, Chen XL, Zhen L, Ge C, Zhao YQ, et al. In vitro assessment of the glucose-lowering effects of berberubrine-9-O-beta-D-glucuronide, an active metabolite of berberubrine. Acta Pharmacol Sin. 2017;38:351–361.